https://www.selleckchem.com/pr....oducts/golvatinib-e7
. The study has identified the potential application of advanced biosensors as standardized clinical diagnostic tools for AD, evolving the way for new and efficient AD control with minimum economic and social burden. After clinical trial, nanobiosensors for measuring Aβ and Tau simultaneously possess innovative diagnosis of AD to provide significant contributions to primary Alzheimer's care intervention. The study has identified the potential application of advanced biosensors as standardized clinical diagnostic tools for AD, e
Like
Comment
Share
